Recurrent low-energy femoral shaft fractures and osteonecrosis of the jaw in a case of multiple myeloma treated with bisphosphonates.
Grasko
Jonathan M
JM
Department of Core Clinical Pathology & Biochemistry, PathWest Laboratory Medicine, Royal Perth Hospital, Perth, Australia.
Herrmann
Richard P
RP
Vasikaran
Samuel D
SD
D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003428:Cross Infection; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D004927:Escherichia coli Infections; D017809:Fatal Outcome; D005264:Femoral Fractures / Q000209:etiology*; D005598:Fractures, Spontaneous / Q000209:etiology*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects*; D007275:Injections, Intravenous; D008297:Male; D008439:Maxillary Diseases / Q000139:chemically induced*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy*; D010020:Osteonecrosis / Q000139:chemically induced*; D010022:Osteopetrosis / Q000139:chemically induced; D012008:Recurrence; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid